Cargando…
Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report
Purpose: To report a case of severe mpox in a newly diagnosed HIV patient concerning for Immune Reconstitution Inflammatory Syndrome (IRIS) and/or tecovirimat resistance and to describe the management approach in the setting of refractory disease. Case: 49-year-old man presented with 2 weeks of peri...
Autores principales: | Martinez, Andres E., Frattaroli, Paola, Vu, Christine A., Paniagua, Lizy, Mintz, Joel, Bravo-Gonzalez, Andres, Zamudio, Paola, Barco, Astrid, Rampersad, Aruna, Lichtenberger, Paola, Gonzales-Zamora, Jose A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051473/ https://www.ncbi.nlm.nih.gov/pubmed/36992234 http://dx.doi.org/10.3390/vaccines11030650 |
Ejemplares similares
-
Tecovirimat for the treatment of severe Mpox in Germany
por: Hermanussen, Lennart, et al.
Publicado: (2023) -
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023
por: Smith, Todd G., et al.
Publicado: (2023) -
Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital
por: Mondi, Annalisa, et al.
Publicado: (2023) -
Isolation and characterization of cidofovir resistant vaccinia viruses
por: Becker, Marie N, et al.
Publicado: (2008) -
2684. Characteristics of mpox patients treated with Tecovirimat: a single center review
por: Vargas, Robert, et al.
Publicado: (2023)